원문정보
초록
영어
The oxazolidinones represent a novel chemical class of synthetic antimicrobial agents. DA-7218 (re-coded as TR-701 by Trius Therapeutics after in-licensing) is a second generation oxazolidinone antibacterial prodrug. It is a potent inhibitor of Gram-positive bacterial
pathogens such as methicillin-resistant Staphylococccus aureus, penicillin-resistant Streptococcus pneumoniae and vancomycin-resistant Enterococcus spp. DA-7218 is also active against pathogens that have developed resistance to first generation oxazolidinones such as
linezolid-resistant S. aureus and linezolid-resistant Enterococcus spp. With a long half-life, high bioavailability and solubility and high potency, DA-7218 will provide clinicians with flexible dosing and a possible shorter course of therapy thereby enabling the early transition of hospitalized patients from IV to oral treatment and subsequent early discharge from the hospital. DA-7218 successfully completed Phase I and Phase II clinical trials in the US. In a recent Phase II clinical trail for treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, DA-7218 was well tolerated and achieved high clinical cure rates in all doses evaluated. In this presentation, overall progress of the development of DA-7218 will be discussed.